Categories: Wire Stories

Aragen Announces Expansion of Discovery Research Agreement with Boehringer Ingelheim

HYDERABAD, India–(BUSINESS WIRE)–#Aragen–Aragen Life Sciences (formerly GVK BIO), a leading Contract Research and Development Organization, headquartered out of Hyderabad, India, announces an expansion of their discovery research agreement with Boehringer Ingelheim, with the goal of accelerating the discovery pipeline of Boehringer Ingelheim.

This preferred partnership allows Boehringer Ingelheim, a leading research driven pharmaceutical company, to incorporate several design elements, synthesize, profile, and then characterize a wide range of chemotypes against key targets of interest in swift optimization cycles. The partnership also allows for the integrated up-scaling of compounds for larger pre-clinical studies. Biology screening of appropriate chemical moieties to drive decision making with speed and accuracy is also included in the partnership. Aragen will dedicate a sizeable portion of its campus in Hyderabad to support this alliance.

“We at Aragen believe that �In Every Molecule is the Possibility for Better Health’, and are excited about the opportunity to expand our partnership with Boehringer Ingelheim, a global leader in the discovery and development of novel medicines. It has been our privilege to collaborate with the scientists at Boehringer Ingelheim, and we thank them for their trust and confidence in the Aragen team. Together, we look forward to advancing Boehringer Ingelheim’s innovative approaches into successful clinical outcomes that can have the potential to ultimately benefit patients,” said Manni Kantipudi, CEO at Aragen.

About Aragen

Aragen Life Sciences Pvt Ltd (“Aragen”) is a global leader in providing discovery, development and manufacturing solutions for life sciences firms. With a team of over 3100 professionals, and through a network of sites around the world, we offer a seamless, integrated platform to advance customer programs from discovery through commercialization for both small molecules and biologics. Established in 2001, Aragen now serves over 450 customers worldwide across multiple modalities and therapeutic areas. For more information, visit www.aragen.com

Contacts

Aragen Life Sciences: Sarat Patanaik, +91 95732 80064, sarat.patanaik@aragen.com
MediaMedic Communications Pvt.Ltd.: Bhavna Pathak, +918830654608, info@mediamedichealth.com

Alex

Recent Posts

ISCA Unveils Bold Plan to Future-Proof Singapore’s Small and Medium-Sized Accounting Practices

SINGAPORE - Media OutReach Newswire - 16 December 2025 - Small and Medium-Sized Accounting Practices…

2 hours ago

Leeds Capital and MIO Trust Are Proud to Announce Their Collaboration on an AI‑Driven Multi‑Asset Trust Focused on Digital Assets and Precious Metals

SYDNEY, AUSTRALIA - Media OutReach Newswire - 16 December 2025 - Leeds Capital and MIO…

3 hours ago

Optimistic Hong Kong Ecommerce Merchants Report Growth, But Hidden Payment Friction Is Eroding Up to 10% of Revenue, Aspire Report Finds

Despite 64% reporting revenue growth, 91% of merchants face payment friction HONG KONG SAR -…

4 hours ago

Hong Kong Launches Its First Dental Innovation Incubation Programme

HONG KONG SAR - Media OutReach Newswire - 16 December 2025 - The University of…

5 hours ago

GEELY Opens Worlds Largest Vehicle Testing Centre, Meeting the New Benchmark in Global Automotive Safety

NINGBO, CHINA - Media OutReach Newswire - 16 December 2025 - Geely Auto Group today…

5 hours ago

Japan’s Hokkaido University Strengthens International Engagement Ahead of Its 150th Anniversary

“Hokkaido University 150 Initiative” Held at One&Co open space in Tanjong Pagar, SingaporeSINGAPORE - Media…

6 hours ago